Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Reporter Virgin Islands.
Press releases published on May 5, 2025
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
GlobeNewswire
·
May 5, 2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
GlobeNewswire
·
May 5, 2025
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the …
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
GlobeNewswire
·
May 5, 2025
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, …
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
GlobeNewswire
·
May 5, 2025
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high response rates with multiple complete …
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
GlobeNewswire
·
May 5, 2025
SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of …
Voreifarem Partners with SwfcNrho Exchange to Create a Global New Paradigm for Medical Data Valuation
GlobeNewswire
·
May 5, 2025
New York, NY, May 05, 2025 (GLOBE NEWSWIRE) -- Recently, Voreifarem, the world’s first digital health project built on the core architecture of "medical chips + blockchain" (token abbreviation: IER), officially launched on the international mainstream …
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, …
Sagitec Awarded MainePERS Project for a Modern Pension Administration System
GlobeNewswire
·
May 5, 2025
ST. PAUL, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sagitec is proud to announce that it has been awarded the Maine Public Employees Retirement System (MainePERS) project. This achievement is a testament to Sagitec's commitment to adhering to the vision that …
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
GlobeNewswire
·
May 5, 2025
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene Administration of OPGx-LCA5 by …
IDI Integrates with Ping Identity’s PingOne DaVinci to Deliver Powerful Identity Insights Across the Consumer Journey
GlobeNewswire
·
May 5, 2025
BOCA RATON, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- Interactive Data, LLC (“IDI”), a red violet company (NASDAQ: RDVT) and leader in identity verification and risk mitigation, today announced a new integration with Ping Identity, a leader in securing …
Study Shows Large Improvements in Long COVID Symptoms and Return to Work
GlobeNewswire
·
May 5, 2025
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Researchers at the University of Alabama at Birmingham (UAB) have identified what is believed to be the first intervention found in a randomized controlled trial to show large and very large improvements in …
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
GlobeNewswire
·
May 5, 2025
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle …
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
GlobeNewswire
·
May 5, 2025
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the …
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
GlobeNewswire
·
May 5, 2025
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company …
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
GlobeNewswire
·
May 5, 2025
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …
BigCommerce Taps Technology Industry Veteran with Strong Record of Innovation as Chief Product Officer
GlobeNewswire
·
May 5, 2025
AUSTIN, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors, today announced that Vipul Shah has joined the company …
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
GlobeNewswire
·
May 5, 2025
Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “ …
PFMcrypto Launches the Best Free Digital Asset Management Platform in 2025, Attracting Millions Worldwide
GlobeNewswire
·
May 5, 2025
New York, May 05, 2025 (GLOBE NEWSWIRE) -- In a year where passive income is more important than ever, PFMcrypto announces the expansion of its free digital asset management platform, now recognized as the most trusted way to earn passive income without …
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
GlobeNewswire
·
May 5, 2025
– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the …